When substantial fat loss occurs, circulating estrogen levels may fluctuate, temporarily disrupting the delicate hormonal balance required for regular ovulation and menstruation
Changes in Mood or Mental Health : While less common, changes in mood or mental health, such as depression or anxiety, should be taken seriously
There should be high vigilance to look for Hunner lesions in men who present with chronic pelvic pain that is worse with bladder filling, associated with urinary frequency and strong urge to urinate, and in whom the diagnosis of CP/CPPSis in doubt, or do not respond to conventional treatments of CP/CPPS
Shimo, H
A 72-week clinical trial resulted in 96% of the individuals losing 5% or more of their starting body weight after consuming Mounjaro
Sources 0990 Effect of Semaglutide on Apnea Hypopnea Index in Female Adolescents with Polycystic Ovary Syndrome and Obesity, Sleep [accessed 16 October 2025] Abstract P3134: Semaglutide Versus Liraglutide and Incidence of Diabetes and Cardiovascular Disease: an Analysis of Real-World Data, Circulation [accessed 16 October 2025] Anti-inflammatory benefits of semaglutide: State of the art, Journal of Clinical and Translational Endocrinology [accessed 16 October 2025] Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US, Alzheimers and Dementia [accessed 16 October 2025] Diabetes MellitusRelated AllCause and Cardiovascular Mortality in a National Cohort of Adults, JAHA [accessed 16 October 2025] Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials, The Lancet [accessed 16 October 2025] Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes, NEJM [accessed 16 October 2025] Effect of weight loss on cardiometabolic risk: observational analysis of two randomised controlled trials of community weight-loss programmes, BJGP [accessed 16 October 2025] ESC 2025: Novo Nordisks Wegovy superior to Zepbound in reducing CV events, Clinical Trials Arena [accessed 16 October 2025] GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity, JAMA Oncology [accessed 16 October 2025] MHRA approves GLP 1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, MHRA [accessed 16 October 2025] Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation [accessed 16 October 2025] Obesity and cardiovascular disease: mechanistic insights and management strategies
